Addex Therapeutics (ADXN) said Thursday it has regained full ownership of its experimental epilepsy treatment after Johnson & Johnson (JNJ) owned J&J Innovative Medicine ended their collaboration.
The asset was returned following J&J Innovative Medicine's prior decision to halt further development, the company said.
Addex said the drug, which targets the mGlu2 receptor, has already undergone three mid-stage trials and comes with a comprehensive dataset for future clinical planning.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。